Gonadotrophin-releasing hormone antagonists for assisted reproductive technology (Q24234608)

1

0 references

Mohamed AFM Youssef

2

0 references

Mohamed Aboulghar

3

0 references

Monique D. Sterrenburg

5

0 references

Janine G Smit

6

0 references

Ahmed M Abou-Setta

Cochrane Database of Systematic Reviews

7

0 references

publication date

11 May 2011

0 references

published in

0 references

cites work

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparison of mild stimulation and conventional stimulation in ART outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol--a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

GnRH antagonist in IVF poor-responder patients: results of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparison of follicular fluid and serum cytokine concentrations in women undergoing assisted reproductive treatment with GnRH agonist long and antagonist protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Efficiency of antagonist IVF cycle programming by estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

A comparative study on the outcomes of in vitro fertilization between women with polycystic ovary syndrome and those with sonographic polycystic ovary-only in GnRH antagonist cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

The psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing gnRH agonist versus antagonist protocols for ovarian hyperstimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

GnRH agonist versus GnRH antagonist in poor ovarian responders: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Does physicians' experience influence in vitro fertilization success in patients undergoing controlled ovarian hyperstimulation with GnRH antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Gonadotrophin-releasing hormone antagonists for assisted conception

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Characteristics of progesterone changes in women with subtle progesterone rise in recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

Comparison of different treatment strategies in IVF with cumulative live birth over a given period of time as the primary end-point: methodological considerations on a randomized controlled non-inferiority trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

Cost-effectiveness of a mild compared with a standard strategy for IVF: a randomized comparison using cumulative term live birth as the primary endpoint

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021

A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB3

7 January 2021